Welcome to our dedicated page for ICON PLC SEC filings (Ticker: ICLR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for ICON plc (NASDAQ: ICLR), a Dublin, Ireland‑based clinical research organisation operating in the research and development in biotechnology industry. As a foreign private issuer, ICON files an annual report on Form 20‑F and furnishes current information on Form 6‑K.
ICON’s Form 6‑K submissions include press releases and other information made public in its home market or to shareholders. Recent 6‑K filings incorporate quarterly financial results, unaudited interim financial statements, updates on financial guidance, details of vaccine study developments, conference call schedules, participation in investor and healthcare conferences, and announcements such as CEO transitions and annual general meeting outcomes.
The company’s financial statements and related disclosures, referenced in its filings, present information on revenue, costs and expenses, income from operations, net income, cash flows and balance sheet items. They also describe elements of ICON’s capital structure, including bank credit lines, loan facilities and senior secured notes, as well as goodwill and intangible assets such as customer relationships, trade names, technology‑based assets and order or production backlog.
Through this filings page, users can review ICON’s regulatory history, including how it reports non‑GAAP measures like adjusted EBITDA, adjusted net income and adjusted diluted earnings per share, and the items excluded from those metrics. Filings are sourced in real time from the SEC’s EDGAR system, and AI‑powered tools on Stock Titan can help summarise lengthy documents, highlight key sections and make complex accounting and disclosure topics easier to understand for investors and researchers following ICON plc.
Barry Edward Balfe submitted a Form 144 notice relating to proposed sales of Common stock and the filing lists restricted stock units that vested under an S-8 plan. The filing shows 566 shares sold in the past three months on 03/04/2026 for $61,836.97. The document also lists RSUs that vested on 03/06/2026 totaling 812 and 2,050 shares under the issuer's S-8 registered plan, described as "Services Rendered."
Artisan Partners files an amended Schedule 13G reporting beneficial ownership of 8,361,303 Ordinary Shares, equal to
Issuer filed Form 144 reporting sale-related notices for vested restricted common stock. The filing lists two restricted stock vesting events on
Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd report a combined 5.5% passive stake in ICON plc’s common stock as of 12/31/2025. They beneficially own 4,214,661 shares in total, with each firm holding sole voting and dispositive power over its respective shares.
Both institutions classify themselves as non-U.S. investment adviser equivalents and state the shares are held in the ordinary course of business, not to change or influence control of ICON plc or participate in any control-related transactions.
ICON plc is delaying the release of its fourth quarter and full year 2025 earnings, now planning to report on or prior to April 30, 2026. The company’s audit committee has launched an internal investigation, led by outside counsel and forensic and technical accounting firms, into certain accounting practices and controls, primarily around revenue recognition for 2023 through 2025.
ICON is reviewing the design and operation of its internal controls over financial reporting and expects to report one or more material weaknesses. Preliminary indications are that revenue in 2023 and 2024 may have been overstated by less than two percent for each fiscal year. Because of the investigation and related reporting delays, ICON is withdrawing its previously issued 2025 full year financial guidance and is not yet able to communicate 2025 financial performance. The company states the investigation has not identified any impact to customers from the practices under review.
ICON plc filed a Form 6-K as a foreign private issuer for November 2025. The filing mainly furnishes an exhibit stating that ICON plc will present at the Jefferies London Healthcare Conference.
The report confirms ICON files annual reports on Form 20-F and is signed by Chief Financial Officer Nigel Clerkin on November 12, 2025.
ICON plc (ICLR) filed a Form 6‑K with Q3 2025 results and updates. Revenue was $2,042,812 thousand for the quarter and $6,061,501 thousand for the nine months. Q3 net income was $2,355 thousand (basic EPS $0.03) versus $197,128 thousand a year ago, driven by a non‑cash goodwill impairment of $165,300 thousand recorded in the quarter. Income from operations was $86,584 thousand versus $285,434 thousand in Q3 2024.
The company executed significant buybacks: 4,504,330 shares were redeemed in 2025 for $750,000 thousand in total consideration, with remaining authorization of $750,000 thousand as of October 23, 2025. Cash and cash equivalents were $468,888 thousand, and total debt was $3,424,129 thousand at September 30, 2025. Net cash provided by operating activities for the nine months was $802,043 thousand.
ICON recorded restructuring charges of $82,296 thousand year‑to‑date and improved accumulated other comprehensive loss to $(86,944) thousand. Unsatisfied performance obligations were approximately $14.0 billion, with 51% expected to be recognized over the next 12 months. The company noted a BARDA stop work notice affected a large COVID vaccine study, with about half of the planned 10,000 participants enrolled and continued follow‑up per protocol.
ICON plc (ICLR) insider filed a Form 144 to sell 18,901 common shares with an aggregate market value of $3,594,781.19. The shares are scheduled for sale on or about 10/02/2025 on NASDAQ.
The filing shows the 18,901 shares were acquired on 10/01/2025 as restricted stock that vested under a registered plan and were issued by the issuer for services rendered. The filing reports 77,772,130 shares outstanding and indicates no securities sold by the filer in the past three months.